2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4101 Venetoclax targets pathogenic T cell subsets to attenuate CAR-T-associated IEC-HS

Yinqiang Zhang, PhD, Mengyi Du2, Yingying Li3, Qiaolin Liu4, Heng Mei, MD, PhD5
1 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background

Chimeric Antigen Receptor T cell (CAR-T) therapy has achieved remarkable therapeutic efficacy in relapsed/refractory hematological malignancies. However, immune effector cell associated hemophagocytic lymphohistiocytosis like syndrome (IEC-HS), a delayed and life threatening severe complication of CAR-T treatment, remains poorly characterized regarding its clinical features and immunopathological mechanisms. Aberrant secondary expansion of CAR-T cells and cytokine mediated inflammatory cascades are implicated in IEC-HS pathogenesis, yet the key immune cell subsets driving this complication are incompletely defined. Beyond inducing tumor apoptosis, B cell lymphoma 2 (BCL-2) inhibitors exert immunomodulatory effects by reshaping T cell subset balance and immune microenvironment, which provides a promising therapeutic rationale for intervening IEC-HS.

Methods

Single-cell RNA sequencing (scRNA-seq) was performed to characterize distinctive immune subsets in IEC-HS and identify key molecular targets. CAR-T cell-induced animal models were established to validate the pathogenesis of IEC-HS. In vitro lactate dehydrogenase (LDH) cytotoxicity assays and flow cytometry were applied to evaluate the regulatory effects of BCL-2 inhibitors on CAR-T cell function. Additionally, an HLH murine model was utilized to verify the therapeutic efficacy of venetoclax against IEC-HS.

Results

A passive murine model was established via infusion of high-dose CAR-T cells. Model mice exhibited typical IEC-HS-like manifestations including lethargy, splenomegaly, and increased hemophagocytes in the bone marrow. The proportion of circulating CAR-T cells was significantly elevated (15.2% vs. 4.2%, P=0.0064), whereas serum levels of interleukin (IL)-6, IL-10 and interferon (IFN)-γ showed no significant changes at the early disease stage. ScRNA-seq profiling of CAR-T infusion products from patients with IEC-HS versus those with CRS only demonstrated a reduced CD4?/CD8? ratio in the IEC-HS group. We identified a unique CXCR3?NKG7?CD8? T cell subset that highly expressed cytotoxic effector genes, activation/exhaustion signatures, and the anti-apoptotic gene BCL2. Notably, the relative abundance of this CXCR3?NKG7?CD8? T-cell subset was significantly higher in CAR-T infusion products from patients who subsequently developed IEC-HS compared with those with CRS only. Furthermore, this pathogenic CXCR3?NKG7?CD8? T-cell subset was further expanded during the clinical onset of IEC-HS relative to its frequency in the pre-infusion CAR-T product. In vitro experiments demonstrated that venetoclax, a BCL-2 inhibitor, potently suppressed excessive CAR-T cell expansion, promoted the transition of CD8? T cells toward naive/central memory phenotypes, while preserving their anti-tumor cytotoxicity and activation status. In the CpG oligodeoxynucleotide-induced HLH mouse model, venetoclax treatment alleviated splenomegaly (280.8 mg vs. 362.6 mg, P=0.0028) and ameliorated peripheral-blood cytopenia, without significant suppression of IFN-γ production by splenic CD8? T cells. Venetoclax improved HLH-associated pathological phenotypes while maintaining the immune function of splenic CD8? T cells.

Conclusions

Our findings reveal characteristic immune alterations within CAR-T infusion products associated with IEC-HS. BCL-2 inhibition by venetoclax targets and modulates CAR-T driven immune dysregulation to mitigate IEC-HS related pathological phenotypes. Therefore, we preliminarily validate the feasibility of BCL-2 inhibition as a “toxicity sparing, efficacy preserving” intervention strategy for this fatal CAR-T associated complication.

 

Yinqiang Zhang, PhD: No relevant conflicts of interest to declare.